persmedРоссийский журнал персонализированной медициныRussian Journal for Personalized Medicine2782-38062782-3814ФОНД АЛМАЗОВА10.18705/2782-3806-2022-2-1-51-62persmed-29Research ArticleОБЗОРЫREVIEWERSМикробная персонифицированная терапия как новый инструмент лечащего врачаMicrobial personified therapy as an instrument of medical doctor in the futureСуворовА. Н.SuvorovA. N.

Суворов Александр Николаевич, доктор медицинских наук, профессор, член-корреспондент РАН, заведующий отделом молекулярной микробиологии ФГБНУ «Институт экспериментальной медицины»

ул. Академика Павлова, д. 12., Санкт-Петербург, 197376

Suvorov Alexander N., MD, Professor, Corresponding Member of the Russian Academy of Sciences, Head of the Department of Molecular Microbiology of the Institute of Experimental Medicine

Academician Pavlov str. 12, Saint Petersburg, 197376

suvorov.an@iemspb.ruНаучный центр мирового уровня «Центр персонализированной медицины»; Федеральное государственное бюджетное научное учреждение «Институт экспериментальной медициныРоссияWorld-Class Research Center for Personalized Medicine; Institute of Experimental medicineRussian Federation202204042022215162Copyright © Суворов А.Н., 20222022Суворов А.Н.Suvorov A.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://persmed.elpub.ru/jour/article/view/29

В обзоре обсуждаются современные представления о микробиоте, об ее организации и значении для функционирования человеческого организма. Представлены данные о значимости изменений микробного состава в случае дисбиоза и стратегии современного врача-клинициста, направленные на восстановление микробного сообщества, свойственного каждому человеку. Освещена позиция автора в отношении к микробной терапии посредством экзогенно выращенных микроорганизмов (пробиотиков, аутопробиотиков и фекальной трансплантации) и введенных в организм человека в условиях дисбиоза.

The review discusses modern concepts of microbiota, its organization and significance for the functioning of the human body. The data on the significance of changes in the microbial composition in the case of dysbiosis and the strategies of a modern clinician aimed at restoring the microbial community inherent in each person are presented. The author’s position in relation to microbial therapy by means of exogenously grown microorganisms (probiotics, autoprobiotics and fecal transplantation) being introduced into the human body under conditions of dysbiosis are described.

аутопробиотикидисбиозинфекционные заболеванияклинические испытаниямикробиотамикробная терапияпробиотикиAutoprobioticclinical trialsdysbiosisinfectionmicrobial therapymicrobiotaprobioticReferencesPessione E. Lactic acid bacteria contribution to gut microbiota complexity: lights and shadows. Front Cell Infect Microbiol. 2012; 2:86.Pessione E. Lactic acid bacteria contribution to gut microbiota complexity: lights and shadows. Front Cell Infect Microbiol. 2012; 2:86.Kumar M, Nagpal R, Kumar R, Hemalatha R, Verma V, Kumar A, Chakraborty C, Singh B, Marotta F, Jain S, Yadav H. Cholesterollowering probiotics as potential biotherapeutics for metabolic diseases. Exp Diabetes Res. 2012:902917.Kumar M, Nagpal R, Kumar R, Hemalatha R, Verma V, Kumar A, Chakraborty C, Singh B, Marotta F, Jain S, Yadav H. Cholesterollowering probiotics as potential biotherapeutics for metabolic diseases. Exp Diabetes Res. 2012:902917.Ulsemer P, Toutounian K, Kressel G, Schmidt J, Karsten U, Hahn A and Goletz S. Safety and tolerance of Bacteroides xylanisolvens DSM 23964 in healthy adults Beneficial Microbes, June 2012; 3(2): 99–111.Ulsemer P, Toutounian K, Kressel G, Schmidt J, Karsten U, Hahn A and Goletz S. Safety and tolerance of Bacteroides xylanisolvens DSM 23964 in healthy adults Beneficial Microbes, June 2012; 3(2): 99–111.Hyland NP, Quigley EM, Brint E. Microbiotahost interactions in irritable bowel syndrome: Epithelial barrier, immune regulation and brain-gut interactions. World J Gastroenterol. 2014 Jul 21;20(27):8859–8866.Hyland NP, Quigley EM, Brint E. Microbiotahost interactions in irritable bowel syndrome: Epithelial barrier, immune regulation and brain-gut interactions. World J Gastroenterol. 2014 Jul 21;20(27):8859–8866.Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI (2006) An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444(7122): 1027–1031.Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI (2006) An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444(7122): 1027–1031.Bruce-Keller AJ, Salbaum JM, Luo M, Blanchard E 4th, Taylor CM, Welsh DA, Berthoud HR. Obese-type Gut Microbiota Induce Neurobehavioral Changes in the Absence of Obesity. Biol Psychiatry. 2014 Jul 18. pii: S0006-3223(14)00520-4.Bruce-Keller AJ, Salbaum JM, Luo M, Blanchard E 4th, Taylor CM, Welsh DA, Berthoud HR. Obese-type Gut Microbiota Induce Neurobehavioral Changes in the Absence of Obesity. Biol Psychiatry. 2014 Jul 18. pii: S0006-3223(14)00520-4.Tilg H, Moschen AR. Microbiota and diabetes: an evolving relationship.Gut. 2014 Sep;63(9):1513–21.Tilg H, Moschen AR. Microbiota and diabetes: an evolving relationship.Gut. 2014 Sep;63(9):1513–21.Wang X, Ota N, Manzanillo P, Kates L, ZavalaSolorio J, Eidenschenk C, Zhang J, Lesch J, Lee WP, Ross J, Diehl L, van Bruggen N, Kolumam G, Ouyang W. Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes.Nature. 2014 Aug 6.Wang X, Ota N, Manzanillo P, Kates L, ZavalaSolorio J, Eidenschenk C, Zhang J, Lesch J, Lee WP, Ross J, Diehl L, van Bruggen N, Kolumam G, Ouyang W. Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes.Nature. 2014 Aug 6.Ito M, Adachi-Akahane S. Inter-organ communication in the regulation of lipid metabolism: focusing on the network between the liver, intestine, and heart. J Pharmacol Sci. 2013;123(4):312–7].Ito M, Adachi-Akahane S. Inter-organ communication in the regulation of lipid metabolism: focusing on the network between the liver, intestine, and heart. J Pharmacol Sci. 2013;123(4):312–7].Rinninella E, Cintoni M, Raoul P, et al. Food Components and Dietary Habits: Keys for a Healthy Gut Microbiota Composition. Nutrients. 2019;11(10):2393. Published 2019 Oct 7. DOI:10.3390/nu11102393.Rinninella E, Cintoni M, Raoul P, et al. Food Components and Dietary Habits: Keys for a Healthy Gut Microbiota Composition. Nutrients. 2019;11(10):2393. Published 2019 Oct 7. DOI:10.3390/nu11102393.Manco M. Gut microbiota and developmental programming of the brain: from evidence in behavioral endophenotypes to novel perspective in obesity. 2012. Front Cell Infect Microbiol 2:109. Epub 2012. 49.(53).Manco M. Gut microbiota and developmental programming of the brain: from evidence in behavioral endophenotypes to novel perspective in obesity. 2012. Front Cell Infect Microbiol 2:109. Epub 2012. 49.(53).Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science. 2012;336:1268–1273.Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science. 2012;336:1268–1273.Swidsinski A, Loening-Baucke V, Lochs H, Hale LP. Spatial organization of bacterial flora in normal and inflamed intestine: a fluorescence in situ hybridization study in mice. World J Gastroenterol. 2005;11: 1131–1140.Swidsinski A, Loening-Baucke V, Lochs H, Hale LP. Spatial organization of bacterial flora in normal and inflamed intestine: a fluorescence in situ hybridization study in mice. World J Gastroenterol. 2005;11: 1131–1140.Pelaseyed T, Bergström J, Gustafsson J, et al. Mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system. Immunological Reviews Volume 260, Issue 1, pages 8–20, 19 Jun 2014. DOI: 10.1111/imr.12182.Pelaseyed T, Bergström J, Gustafsson J, et al. Mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system. Immunological Reviews Volume 260, Issue 1, pages 8–20, 19 Jun 2014. DOI: 10.1111/imr.12182.Alexander KL, Targan SR, Elson CO 3rd. Microbiota activation and regulation of innate and adaptive immunity. Immunol Rev. 2014 Jul;260(1):206– 20. DOI: 10.1111/imr.12180.Alexander KL, Targan SR, Elson CO 3rd. Microbiota activation and regulation of innate and adaptive immunity. Immunol Rev. 2014 Jul;260(1):206– 20. DOI: 10.1111/imr.12180.Garcia-Gutierrez E, Mayer MJ, Cotter PD, Narbad A. Gut microbiota as a source of novel antimicrobials. Gut Microbes. 2019; 10(1):1–21.Garcia-Gutierrez E, Mayer MJ, Cotter PD, Narbad A. Gut microbiota as a source of novel antimicrobials. Gut Microbes. 2019; 10(1):1–21.Peng L, Li ZR, Green RS, Holzman IR, Lin J. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr. 2009 Sep; 139(9):1619–25.Peng L, Li ZR, Green RS, Holzman IR, Lin J. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr. 2009 Sep; 139(9):1619–25.Tannock G.W. 2010.The Bowel Microbiota and Inflammatory Bowel Diseases. Int J Inflam 954051. PMCID: PMC3004003.Tannock G.W. 2010.The Bowel Microbiota and Inflammatory Bowel Diseases. Int J Inflam 954051. PMCID: PMC3004003.Zhao Y, Chen F, Wu W, et al. GPR43 mediates microbiota metabolite SCFA regulation of antimicrobial peptide expression in intestinal epithelial cells via activation of mTOR and STAT3. Mucosal Immunol. 2018;11(3):752–762. DOI:10.1038/mi.2017.118.Zhao Y, Chen F, Wu W, et al. GPR43 mediates microbiota metabolite SCFA regulation of antimicrobial peptide expression in intestinal epithelial cells via activation of mTOR and STAT3. Mucosal Immunol. 2018;11(3):752–762. DOI:10.1038/mi.2017.118.Valeri M, Rossi Paccani S, Kasendra M, Nesta B, Serino L, Pizza M, et al. (2015) Pathogenic E. coli Exploits SslE Mucinase Activity to Translocate through the Mucosal Barrier and Get Access to Host Cells. PLoS ONE 10(3): e0117486. https://doi.org/10.1371/journal.pone.0117486Valeri M, Rossi Paccani S, Kasendra M, Nesta B, Serino L, Pizza M, et al. (2015) Pathogenic E. coli Exploits SslE Mucinase Activity to Translocate through the Mucosal Barrier and Get Access to Host Cells. PLoS ONE 10(3): e0117486. https://doi.org/10.1371/journal.pone.0117486Gray DA, Wenzel M. Multitarget Approaches against Multiresistant Superbugs. ACS Infect Dis. 2020 Jun 12;6(6):1346–1365. DOI: 10.1021/acsinfecdis.0c00001. Epub 2020 Mar 19. PMID: 32156116; PMCID: PMC7307902.Gray DA, Wenzel M. Multitarget Approaches against Multiresistant Superbugs. ACS Infect Dis. 2020 Jun 12;6(6):1346–1365. DOI: 10.1021/acsinfecdis.0c00001. Epub 2020 Mar 19. PMID: 32156116; PMCID: PMC7307902.Suvorov A. Gut microbiota, probiotics, and human health. Biosci Microbiota Food Health. 2013;32:81–91. add DOI: 10.12938/bmfh.32.81.Suvorov A. Gut microbiota, probiotics, and human health. Biosci Microbiota Food Health. 2013;32:81–91. add DOI: 10.12938/bmfh.32.81.Malo MS, Alam SN, Mostafa G, Zeller SJ, Johnson PV, Mohammad N, Chen KT, Moss AK, Ramasamy S, Faruqui A, Hodin S, Malo PS, Ebrahimi F, Biswas B, Narisawa S, Millán JL, Warren HS, Kaplan JB, Kitts CL, Hohmann EL, Hodin RA. 2010. Intestinal alkaline phosphatase preserves the normal homeostasis of gut microbiota. Gut 59:1476–1484].Malo MS, Alam SN, Mostafa G, Zeller SJ, Johnson PV, Mohammad N, Chen KT, Moss AK, Ramasamy S, Faruqui A, Hodin S, Malo PS, Ebrahimi F, Biswas B, Narisawa S, Millán JL, Warren HS, Kaplan JB, Kitts CL, Hohmann EL, Hodin RA. 2010. Intestinal alkaline phosphatase preserves the normal homeostasis of gut microbiota. Gut 59:1476–1484].Carr FJ, Chill D, Maida N. The lactic acid bacteria: a literature survey. Crit. Rev. Microbiol. 2002.28: 281–370 www.gidrm.ru/includes/mktng/marketing.Carr FJ, Chill D, Maida N. The lactic acid bacteria: a literature survey. Crit. Rev. Microbiol. 2002.28: 281–370 www.gidrm.ru/includes/mktng/marketing.Hempel S, Newberry SJ, Maher AR, Wang Z, Miles JN, Shanman R, Johnsen B, Shekelle PG. 2012. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA 307:1959–1969.Hempel S, Newberry SJ, Maher AR, Wang Z, Miles JN, Shanman R, Johnsen B, Shekelle PG. 2012. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA 307:1959–1969.Woo TD, Oka K, Takahashi M, Hojo F, Osaki T, Hanawa T, Kurata S, Yonezawa H, Kamiya S. Inhibition of the cytotoxic effect of Clostridium difficile in vitro by Clostridium butyricum MIYAIRI 588 strain. J Med. Microbiol. 2011;60:1617–1625.Woo TD, Oka K, Takahashi M, Hojo F, Osaki T, Hanawa T, Kurata S, Yonezawa H, Kamiya S. Inhibition of the cytotoxic effect of Clostridium difficile in vitro by Clostridium butyricum MIYAIRI 588 strain. J Med. Microbiol. 2011;60:1617–1625.Ritchie M, Romanuk T. A Meta-Analysis of Probiotic Efficacy for Gastrointestinal. Diseases PLoS One. 2012;7(4): e34938.Ritchie M, Romanuk T. A Meta-Analysis of Probiotic Efficacy for Gastrointestinal. Diseases PLoS One. 2012;7(4): e34938.Verhoog S, Taneri PE, Roa Díaz ZM, et al. Dietary Factors and Modulation of Bacteria Strains of Akkermansia muciniphila and Faecalibacterium prausnitzii: A Systematic Review. Nutrients. 2019;11(7):1565. Published 2019 Jul 11. DOI:10.3390/nu11071565 .Verhoog S, Taneri PE, Roa Díaz ZM, et al. Dietary Factors and Modulation of Bacteria Strains of Akkermansia muciniphila and Faecalibacterium prausnitzii: A Systematic Review. Nutrients. 2019;11(7):1565. Published 2019 Jul 11. DOI:10.3390/nu11071565 .Bergmann KR, Liu SX, Tian R, Kushnir A, Turner JR, Li HL, Chou PM, Weber CR, De Plaen IG Bifidobacteria stabilize claudins at tight junctions and prevent intestinal barrier dysfunction in mouse necrotizing enterocolitis. Am J Pathol. 2013 May; 182(5):1595–606.Bergmann KR, Liu SX, Tian R, Kushnir A, Turner JR, Li HL, Chou PM, Weber CR, De Plaen IG Bifidobacteria stabilize claudins at tight junctions and prevent intestinal barrier dysfunction in mouse necrotizing enterocolitis. Am J Pathol. 2013 May; 182(5):1595–606.Terciolo C, Dapoigny M, Andre F. Beneficial effects of Saccharomyces boulardii CNCM I-745 on clinical disorders associated with intestinal barrier disruption. Clin Exp Gastroenterol. 2019; 12:67–82.Terciolo C, Dapoigny M, Andre F. Beneficial effects of Saccharomyces boulardii CNCM I-745 on clinical disorders associated with intestinal barrier disruption. Clin Exp Gastroenterol. 2019; 12:67–82.Ukena SN, Singh A, Dringenberg U, Engelhardt R, Seidler U, Hansen W, Bleich A, Bruder D, Franzke A, Rogler G, Suerbaum S, Buer J, Gunzer F, Westendorf AM. Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. PLoS One. 2007 Dec 12; 2(12):e1308.Ukena SN, Singh A, Dringenberg U, Engelhardt R, Seidler U, Hansen W, Bleich A, Bruder D, Franzke A, Rogler G, Suerbaum S, Buer J, Gunzer F, Westendorf AM. Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. PLoS One. 2007 Dec 12; 2(12):e1308.Anderson JM, Van Itallie CM. Physiology and function of the tight junction. Cold Spring Harb Perspect Biol. 2009 Aug; 1(2):a002584.Anderson JM, Van Itallie CM. Physiology and function of the tight junction. Cold Spring Harb Perspect Biol. 2009 Aug; 1(2):a002584.Zareie M, Riff J, Donato K, McKay DM, Perdue MH, Soderholm JD, Karmali M, Cohen MB, Hawkins J, Sherman PM. Novel effects of the prototype translocating Escherichia coli, strain C25 on intestinal epithelial structure and barrier function. Cell Microbiol. 2005 Dec; 7(12):1782–97.Zareie M, Riff J, Donato K, McKay DM, Perdue MH, Soderholm JD, Karmali M, Cohen MB, Hawkins J, Sherman PM. Novel effects of the prototype translocating Escherichia coli, strain C25 on intestinal epithelial structure and barrier function. Cell Microbiol. 2005 Dec; 7(12):1782–97.Kamada N, Chen GY, Inohara N, Núñez G. Control of pathogens and pathobionts by the gut microbiota. Nat Immunol. 2013 Jul; 14(7):685–90.Kamada N, Chen GY, Inohara N, Núñez G. Control of pathogens and pathobionts by the gut microbiota. Nat Immunol. 2013 Jul; 14(7):685–90.Farup PG, Jacobsen M, Ligaarden SC, Rudi K. 2012. Probiotics, symptoms, and gut microbiota: what are the relations? A randomized controlled trial in subjects with irritable bowel syndrome. Gastroenterol Res Pract 2012:214102. Epub 2012 Jul 31.Farup PG, Jacobsen M, Ligaarden SC, Rudi K. 2012. Probiotics, symptoms, and gut microbiota: what are the relations? A randomized controlled trial in subjects with irritable bowel syndrome. Gastroenterol Res Pract 2012:214102. Epub 2012 Jul 31.Lee BJ, Bak YT. 2011. Irritable Bowel Syndrome, Gut Microbiota and Probiotics. J Neurogastroenterol Motil 17:252–266.Lee BJ, Bak YT. 2011. Irritable Bowel Syndrome, Gut Microbiota and Probiotics. J Neurogastroenterol Motil 17:252–266.McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol. 2008;14: 2650–2661.McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol. 2008;14: 2650–2661.Galdeano CM, Perdigón G. Role of viability of probiotic strains in their persistence in the gut and in mucosal immune stimulation. J Appl Microbiol. 2004;97(4):673-81. DOI: 10.1111/j.1365-2672.2004.02353.x. PMID: 15357716.Galdeano CM, Perdigón G. Role of viability of probiotic strains in their persistence in the gut and in mucosal immune stimulation. J Appl Microbiol. 2004;97(4):673-81. DOI: 10.1111/j.1365-2672.2004.02353.x. PMID: 15357716.Hurkala J, Lauterbach R, Radziszewska R, Strus M, Heczko P. Effect of a Short-Time Probiotic Supplementation on the Abundance of the Main Constituents of the Gut Microbiota of Term Newborns Delivered by Cesarean Section-A Randomized, Prospective, Controlled Clinical Trial. Nutrients. 2020 Oct 14;12(10):3128. DOI: 10.3390/nu12103128. PMID: 33066338; PMCID: PMC7602088.Hurkala J, Lauterbach R, Radziszewska R, Strus M, Heczko P. Effect of a Short-Time Probiotic Supplementation on the Abundance of the Main Constituents of the Gut Microbiota of Term Newborns Delivered by Cesarean Section-A Randomized, Prospective, Controlled Clinical Trial. Nutrients. 2020 Oct 14;12(10):3128. DOI: 10.3390/nu12103128. PMID: 33066338; PMCID: PMC7602088.Machado MV, Cortez-Pinto H. Gut microbiota and nonalcoholic fatty liver disease. Ann Hepatol. 2012; 11:440–449.Machado MV, Cortez-Pinto H. Gut microbiota and nonalcoholic fatty liver disease. Ann Hepatol. 2012; 11:440–449.Nakamura YK, Omaye ST. Metabolic diseases and pro- and prebiotics: Mechanistic insights. Nutr Metab (Lond). 2012;19:60.PMID:22713169.Nakamura YK, Omaye ST. Metabolic diseases and pro- and prebiotics: Mechanistic insights. Nutr Metab (Lond). 2012;19:60.PMID:22713169.Cani PD, Delzenne NM. Interplay between obesity and associated metabolic disorders: new insights into the gut microbiota. Curr Opin Pharmacol. 2009;9:737–743.Cani PD, Delzenne NM. Interplay between obesity and associated metabolic disorders: new insights into the gut microbiota. Curr Opin Pharmacol. 2009;9:737–743.Macho Fernandez E, Valenti V, Rockel C, Hermann C, Pot B, Boneca IG, Grangette C. Anti-inflammatory capacity of selected lactobacilli in experimental colitis is driven by NOD2-mediated recognition of a specific peptidoglycan derived muropeptide. Gut 2011.60: 1050– 1059.Macho Fernandez E, Valenti V, Rockel C, Hermann C, Pot B, Boneca IG, Grangette C. Anti-inflammatory capacity of selected lactobacilli in experimental colitis is driven by NOD2-mediated recognition of a specific peptidoglycan derived muropeptide. Gut 2011.60: 1050– 1059.Mangalat N, Liu Y, Fatheree NY, Ferris MJ, Van Arsdall MR, Chen Z, Rahbar MH, Gleason WA, Norori J, Tran DQ, Rhoads JM. Safety and Tolerability of Lactobacillus reuteri DSM 17938 and Effects on Biomarkers in Healthy Adults: Results from a Randomized Masked Trial. PLoS One. 2012; 7:e43910.Mangalat N, Liu Y, Fatheree NY, Ferris MJ, Van Arsdall MR, Chen Z, Rahbar MH, Gleason WA, Norori J, Tran DQ, Rhoads JM. Safety and Tolerability of Lactobacillus reuteri DSM 17938 and Effects on Biomarkers in Healthy Adults: Results from a Randomized Masked Trial. PLoS One. 2012; 7:e43910.Petrof EO, Claud EC, Sun J, Abramova T, Guo Y, Waypa TS, He SM, Nakagawa Y, Chang EB. Bacteria-free solution derived from Lactobacillus plantarum inhibits multiple NFkappaB pathways and inhibits proteasome function,” Inflammatory Bowel Diseases. 2009;5: 1537–1547.Petrof EO, Claud EC, Sun J, Abramova T, Guo Y, Waypa TS, He SM, Nakagawa Y, Chang EB. Bacteria-free solution derived from Lactobacillus plantarum inhibits multiple NFkappaB pathways and inhibits proteasome function,” Inflammatory Bowel Diseases. 2009;5: 1537–1547.Schlee M, Harder J, Köten B, Stange EF, Wehkamp J, Fellermann K. Probiotic lactobacilli and VSL#3 induce enterocyte β-defensin 2,” Clinical and Experimental Immunology. 2008; 151: 528–535.Schlee M, Harder J, Köten B, Stange EF, Wehkamp J, Fellermann K. Probiotic lactobacilli and VSL#3 induce enterocyte β-defensin 2,” Clinical and Experimental Immunology. 2008; 151: 528–535.Yoon SS, Sun J.2011. Probiotics, nuclear receptor signaling, and antiinflammatory pathways. Gastroenterol Res Pract. 2011:971938.Yoon SS, Sun J.2011. Probiotics, nuclear receptor signaling, and antiinflammatory pathways. Gastroenterol Res Pract. 2011:971938.Putaala H, Salusjärvi T, Nordström M, Saarinen M, Ouwehand AC, Bech Hansen E, Rautonen N. Effect of four probiotic strains and Escherichia coli O157:H7 on tight junction integrity and cyclo-oxygenase expression. Res Microbiol. 2008 Nov-Dec;159(9-10):692–8. Do.Putaala H, Salusjärvi T, Nordström M, Saarinen M, Ouwehand AC, Bech Hansen E, Rautonen N. Effect of four probiotic strains and Escherichia coli O157:H7 on tight junction integrity and cyclo-oxygenase expression. Res Microbiol. 2008 Nov-Dec;159(9-10):692–8. Do.Ermolenko E, Gromova L, Borschev Yu, Voeikova A, Karaseva A, Ermolenko K, Gruzdkov A, Suvorov A. Influence of different probiotic lactic acid bacteria on microbiota and metabolism of rats with dysbiosis. Biosci Microbiota Food Health. 2013; 32(2):41–49.Ermolenko E, Gromova L, Borschev Yu, Voeikova A, Karaseva A, Ermolenko K, Gruzdkov A, Suvorov A. Influence of different probiotic lactic acid bacteria on microbiota and metabolism of rats with dysbiosis. Biosci Microbiota Food Health. 2013; 32(2):41–49.Abdurasulova IN, Matsulevich AV, Tarasova EA, Kudrjavtsev IV, Serebrjakova MK, Ermolenko EI, Bisaga GN, Klimenko VM, Suvorov AN. Enterococcus faecium L3 and glatiramer acetate ameliorate of experimental allergic encephalomyelitis (EAE) in rats by affecting different populations of immune cells. Benef Microbes. 2016;7(5):719–729.Abdurasulova IN, Matsulevich AV, Tarasova EA, Kudrjavtsev IV, Serebrjakova MK, Ermolenko EI, Bisaga GN, Klimenko VM, Suvorov AN. Enterococcus faecium L3 and glatiramer acetate ameliorate of experimental allergic encephalomyelitis (EAE) in rats by affecting different populations of immune cells. Benef Microbes. 2016;7(5):719–729.Tiwari SK, Dicks LMT, Popov IV, Karaseva A, Ermakov AM, Suvorov A, Tagg JR, Weeks R, Chikindas ML. Probiotics at War Against Viruses: What Is Missing From the Picture? Front Microbiol. 2020 Aug 20;11:1877. DOI: 10.3389/fmicb.2020.01877. PMID: 32973697; PMCID: PMC7468459.Tiwari SK, Dicks LMT, Popov IV, Karaseva A, Ermakov AM, Suvorov A, Tagg JR, Weeks R, Chikindas ML. Probiotics at War Against Viruses: What Is Missing From the Picture? Front Microbiol. 2020 Aug 20;11:1877. DOI: 10.3389/fmicb.2020.01877. PMID: 32973697; PMCID: PMC7468459.Budding AE, Grasman ME, Lin F, Bogaards JA, Soeltan-Kaersenhout DJ, Vandenbroucke-Grauls CM, van Bodegraven AA, Savelkoul PH. ISpro: highthroughput molecular fingerprinting of the intestinal microbiota. FASEB J. 2010;24:4556–4564.Budding AE, Grasman ME, Lin F, Bogaards JA, Soeltan-Kaersenhout DJ, Vandenbroucke-Grauls CM, van Bodegraven AA, Savelkoul PH. ISpro: highthroughput molecular fingerprinting of the intestinal microbiota. FASEB J. 2010;24:4556–4564.Dhar D, Mohanty A. Gut microbiota and Covid-19- possible link and implications. Virus Res. 2020 Aug;285:198018. DOI: 10.1016/j.virusres.2020.198018. Epub 2020 May 13. PMID: 32430279; PMCID: PMC7217790.Dhar D, Mohanty A. Gut microbiota and Covid-19- possible link and implications. Virus Res. 2020 Aug;285:198018. DOI: 10.1016/j.virusres.2020.198018. Epub 2020 May 13. PMID: 32430279; PMCID: PMC7217790.Taghinezhad-S S, Mohseni AH, BermúdezHumarán LG, Casolaro V, Cortes-Perez NG, Keyvani H, Simal-Gandara J. Probiotic-Based Vaccines May Provide Effective Protection against COVID-19 Acute Respiratory Disease. Vaccines (Basel). 2021 May 6;9(5):466. DOI: 10.3390/vaccines9050466. PMID: 34066443; PMCID: PMC8148110.Taghinezhad-S S, Mohseni AH, BermúdezHumarán LG, Casolaro V, Cortes-Perez NG, Keyvani H, Simal-Gandara J. Probiotic-Based Vaccines May Provide Effective Protection against COVID-19 Acute Respiratory Disease. Vaccines (Basel). 2021 May 6;9(5):466. DOI: 10.3390/vaccines9050466. PMID: 34066443; PMCID: PMC8148110.Wang JW, Kuo CH, Kuo FC, Wang YK, Hsu WH, Yu FJ, Hu HM, Hsu PI, Wang JY, Wu DC. Fecal microbiota transplantation: Review and update. J Formos Med Assoc. 2019 Mar;118 Suppl 1:S23-S31. DOI: 10.1016/j.jfma.2018.08.011. Epub 2018 Sep 1. PMID: 30181015.Wang JW, Kuo CH, Kuo FC, Wang YK, Hsu WH, Yu FJ, Hu HM, Hsu PI, Wang JY, Wu DC. Fecal microbiota transplantation: Review and update. J Formos Med Assoc. 2019 Mar;118 Suppl 1:S23-S31. DOI: 10.1016/j.jfma.2018.08.011. Epub 2018 Sep 1. PMID: 30181015.Fang H, Fu L, Wang J. Protocol for Fecal Microbiota Transplantation in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Biomed Res Int. 2018 Sep 13;2018:8941340. DOI: 10.1155/2018/8941340. PMID: 30302341; PMCID: PMC6158944.Fang H, Fu L, Wang J. Protocol for Fecal Microbiota Transplantation in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Biomed Res Int. 2018 Sep 13;2018:8941340. DOI: 10.1155/2018/8941340. PMID: 30302341; PMCID: PMC6158944.Bäumler AJ, Sperandio V. Interactions between the microbiota and pathogenic bacteria in the gut. Nature. 2016 Jul 7;535(7610):85–93.Bäumler AJ, Sperandio V. Interactions between the microbiota and pathogenic bacteria in the gut. Nature. 2016 Jul 7;535(7610):85–93.Pamer EG. Resurrecting the intestinal microbiota to combat antibiotic-resistant pathogens. Science. 2016 Apr 29;352(6285):535–8. DOI: 10.1126/science.aad9382. PMID: 27126035; PMCID: PMC4984266.Pamer EG. Resurrecting the intestinal microbiota to combat antibiotic-resistant pathogens. Science. 2016 Apr 29;352(6285):535–8. DOI: 10.1126/science.aad9382. PMID: 27126035; PMCID: PMC4984266.Suvorov A, Karaseva A, Kotyleva M, et al. Autoprobiotics as an Approach for Restoration of Personalized Microbiota. Front Microbiol. 2018;9:1869. Published 2018 Sep 12. DOI:10.3389/fmicb.2018.01869.Suvorov A, Karaseva A, Kotyleva M, et al. Autoprobiotics as an Approach for Restoration of Personalized Microbiota. Front Microbiol. 2018;9:1869. Published 2018 Sep 12. DOI:10.3389/fmicb.2018.01869.Ермоленко Е.И., Ерофеев Н.П., Захарова Л.Б., Парийская Е.Н., Котылева М.П., Крамская Т.А., Карасева А.Б., Суворов А.Н. Особенности состава микробиоты и моторики кишечника после коррекции экспериментального дисбиоза пробиотическими и аутопробиотическими энтерококками. Экспериментальная и клиническая гастроэнтерология. 2017. № 7 (143). С. 89–96.Ермоленко Е.И., Ерофеев Н.П., Захарова Л.Б., Парийская Е.Н., Котылева М.П., Крамская Т.А., Карасева А.Б., Суворов А.Н. Особенности состава микробиоты и моторики кишечника после коррекции экспериментального дисбиоза пробиотическими и аутопробиотическими энтерококками. Экспериментальная и клиническая гастроэнтерология. 2017. № 7 (143). С. 89–96.Соловьева О.И., Симаненков В.И., Суворов А.Н., Ермоленко Е.И., Шумихина И.А., Свиридо Д.А. Использование пробиотиков и аутопробиотиков в лечении синдрома раздраженной толстой кишки. Экспериментальная и клиническая гастроэнтерология. 2017. № 7 (143). С. 115–120.Соловьева О.И., Симаненков В.И., Суворов А.Н., Ермоленко Е.И., Шумихина И.А., Свиридо Д.А. Использование пробиотиков и аутопробиотиков в лечении синдрома раздраженной толстой кишки. Экспериментальная и клиническая гастроэнтерология. 2017. № 7 (143). С. 115–120.Симаненков В.И., Бакулина Н.В., Тихонов С.В., Ермоленко Е.И., Декканова В.Д., Котылева М.П., Лавренова Н.С., Воропаева Л.С., Коржева М.Д., Суворов А.Н., Цапиева А.Н. Эффективность и безопасность аутопробиотической терапии у пациентов с сахарным диабетом второго типа, Медицинский алфавит. 2020. № 30. С. 48–53.Симаненков В.И., Бакулина Н.В., Тихонов С.В., Ермоленко Е.И., Декканова В.Д., Котылева М.П., Лавренова Н.С., Воропаева Л.С., Коржева М.Д., Суворов А.Н., Цапиева А.Н. Эффективность и безопасность аутопробиотической терапии у пациентов с сахарным диабетом второго типа, Медицинский алфавит. 2020. № 30. С. 48–53.Боровкова Е.А., Алиева Е.В., Ковалев Д.А. и др. Оценка безопасности индигенных лактобацилл кишечника, перспективных в качестве аутопробиотиков. Современная наука: актуальные проблемы теории и практики. Серия: Естественные и технические науки. 2020. № 7. С. 14–19.Боровкова Е.А., Алиева Е.В., Ковалев Д.А. и др. Оценка безопасности индигенных лактобацилл кишечника, перспективных в качестве аутопробиотиков. Современная наука: актуальные проблемы теории и практики. Серия: Естественные и технические науки. 2020. № 7. С. 14–19.Zhang M, Sun K, Wu Yu, Yang Yi, Tso P, Wu Z. Interactions between Intestinal Microbiota and Host Immune Response in Inflammatory Bowel Disease, Frontiers in Immunology. 2017, 8, 942.Zhang M, Sun K, Wu Yu, Yang Yi, Tso P, Wu Z. Interactions between Intestinal Microbiota and Host Immune Response in Inflammatory Bowel Disease, Frontiers in Immunology. 2017, 8, 942.Wopereis H. The first thousand days — intestinal microbiology of early life: establishing a symbiosis. https://doi.org/10.1111/pai.12232Wopereis H. The first thousand days — intestinal microbiology of early life: establishing a symbiosis. https://doi.org/10.1111/pai.12232

The authors declare that there are no conflicts of interest present.